Condition: Adamantinomatous Craniopharyngioma · Recurrent Adamantinomatous Craniopharyngioma · Sponsor: Nationwide Children's Hospital
ACTEMRA (tocilizumab) is an IL-6 receptor antagonist used for the treatment of adult Rheumatoid Arthritis as well as Polyarticular (PJIA) and Systemic (SJIA) Juvenile Idiopathic Arthritis. In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.
This description comes directly from the study's public registry record.
Kelsey H Troyer, PhD · 16147223284 · kelsey.troyer@nationwidechildrens.org
Always discuss trial participation with your own doctor first.
| Children's Hospital Colorado | Aurora, Colorado, United States | Recruiting |
| Children's National Medical Center | Washington D.C., District of Columbia, United States | Recruiting |
| Nicklaus Children's Hospital | Miami, Florida, United States | Active Not Recruiting |
| Duke Children's Hospital | Durham, North Carolina, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
| Nationwide Children's Hospital | Columbus, Ohio, United States | Recruiting |
| Texas Children's Hospital | Houston, Texas, United States | Recruiting |
| Seattle Children's Hospital | Seattle, Washington, United States | Recruiting |
| Sydney Children's Hospital | Randwick, New South Wales, Australia | Recruiting |
| Queensland Children's Hospital | South Brisbane, Queensland, Australia | Recruiting |
| Perth Children's Hospital | Perth, Western Australia, Australia | Recruiting |
| Stollery Children's Hospital | Edmonton, Alberta, Canada | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05233397